Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVATACE-1: Bevacizumab + TACE in Hepatocellular Carcinoma
NCT00280007Phase 2Terminated
- Sponsor
- Medical University of Vienna
- Start
- Jan 2006
- Primary completion
- Dec 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial in hepatocellular carcinoma (HCC) comparing Bevacizumab with Placebo (2 arms). Primary endpoints: Patients without tumor progression at 12 months and Collateral tumor vessel growth on MRT / CT at 12 months. Started Jan 2006; status: terminated.
02
Drugs
bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00280007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00280007.